With a market capitalization (market cap) of $2.04B — a measure of how much the company is worth — GH Research PLC is the 2100th most valuable company in Healthcare as of August 18, 2026. Shares trade at $29.74, down +0.82% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Visit websiteAs of August 18, 2026, GH Research PLC (GHRS) is worth $2.04B — this is its market capitalization, the total value of all its outstanding shares.
GH Research PLC’s market cap is $2.04B, which ranks it #2100 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
GH Research PLC (GHRS) shares trade at $29.74, down 0.82% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025